Save up to 90% on Panitumumab with Coupons, Discount Cards & Patient Assistance Programs

Panitumumab is available as 100 mg/5 mL (20 mg/mL) and 400 mg/20 mL (20 mg/mL) in single-dose vials.

Panitumumab is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): In combination with FOLFOX for first-line treatment. As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

Panitumumab is a monoclonal antibody designed to latch on to EGFR and block growth signals from reaching it. Panitumumab is also called an anti-EGFR therapy. Blocking signals may help stop the growth and survival of cancer cells.

Panitumumab is dosed as follows:

• Administer 6 mg/kg every 14 days as an intravenous infusion over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg)
• Infusion Reactions: Reduce infusion rate by 50% for mild reactions; terminate the infusion for severe infusion reactions
• Dermatologic Toxicity: Withhold or discontinue for severe or intolerable toxicity; reduce dose for recurrent, grade 3 toxicity

Panitumumab is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Panitumumab:

• Skin rash
• Paronychia (infection of the tissue folds around the nails)
• Fatigue
• Nausea
• Diarrhea

Serious side effects are rare with Panitumumab. Contact a healthcare professional if your experience skin or ocular/visual changes, severe diarrhea and dehydration, coughing, wheezing, dyspnea, or new-onset facial swelling.

There are no major drug interactions listed for Panitumumab. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Various FDA-approved generic manufacturers

Panitumumab use can result in fetal harm. Females that can become pregnant should use effective contraception during treatment with Panitumumab, and for at least 2 months after the last dose. Notify your healthcare provider of a known or suspected pregnancy.

• Vectibix